News & Events

• Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
  Published on 2021-05-11
• Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
  Published on 2021-05-04
• Genetic Analysis Joins Microbiome Therapeutics Innovation Group
  Published on 2021-05-03
• Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
  Published on 2021-04-29
• Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
  Published on 2021-04-28
• Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
  Published on 2021-04-15
• Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
  Published on 2021-04-15
• Servatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group
  Published on 2021-03-29
• Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
  Published on 2021-03-12
• Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma
  Published on 2021-03-08
• Microba Life Sciences joins Microbiome Therapeutics Group
  Published on 2021-03-04
• Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis
  Published on 2021-03-02
• Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
  Published on 2021-03-02
• Vedanta Biosciences to Present at Upcoming Investor Conferences
  Published on 2021-03-02
• Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021
  Published on 2021-02-24